Cognition Therapeutics reported a net loss of $4.1 million for the third quarter 2026, driven by higher clinical trial activity for its lead candidate zervimesine. While the loss was narrower than anticipated, the company received a Nasdaq deficiency notice for failing to maintain a minimum bid price of $1.00.
Key Highlights
- Net loss per share of $(0.04) outperformed the analyst consensus estimate of $(0.07).
- Grant income totaled $2.97 million, significantly trailing the consensus expectation of $5.30 million.
- Total liquidity of $49.7 million, comprising $31.5 million in cash and $18.2 million in remaining obligated NIH grants, extends the operational runway into the fourth quarter 2027.
- Received formal Nasdaq non-compliance notice on November 3, 2026, regarding its sub-$1.00 share price, with a deadline of May 3, 2027, to regain compliance.